What Is Ribupatide?

1. What Do the Names Mean?

Ribupatide is the molecule name. Jiangsu Hengrui Pharmaceuticals developed it in China and, in May 2024, licensed rights outside Greater China to Kailera Therapeutics, a U.S. company formed that month to in-license the portfolio, backed by a $300 million Series A cash financing; Kailera listed on Nasdaq in April 2026. The same deal covered the oral GLP-1 tablet HRS-7535, which is why both drugs carry paired Hengrui and Kailera codes (Hengrui program background, Kailera prospectus).

Ribupatide activates both GLP-1 and GIP receptors, two hormone-related pathways involved in metabolic regulation. It shares this receptor class with tirzepatide and with Roche’s enicepatide, but is a distinct molecule (Kailera molecule overview). In Hengrui’s first-in-human study in 90 healthy Chinese volunteers, published in September 2026, the mean half-life after four weekly doses was 7 to 8 days, consistent with once-weekly dosing (He et al., Diabetes Obes Metab 2026).

2. Does a Drug Developed in China Work the Same Elsewhere?

This is the first question Western regulators ask about ribupatide, and Kailera ran a study to answer it before starting Phase 3. Its Phase 1 bridging trial gave a single injection, without dose escalation, to participants of Asian and non-Asian descent: 1, 2 or 3 mg for non-Asian participants and 2 mg for Asian participants, followed for 29 days. Drug exposure was similar in both groups once adjusted for body weight, side effects were similar, and weight fell in a dose-dependent way with no difference between groups (ADA 2026 presentation).

That single-dose study also shows what happens without a gradual ramp: decreased appetite in 62 to 82% of participants, nausea in 25 to 75%, and vomiting in up to 50%. Every later trial escalates the dose over weeks for exactly that reason.

3. Phase 3 Trials and Upcoming Dates

The injection is in global Phase 3. Oral ribupatide is already in Phase 3 in China, while global oral Phase 3 is planned for 2027. Hengrui also reported that the Chinese application for injectable ribupatide for adult weight management was accepted in September 2025 and remained under review in its August 2026 update (Hengrui China status). A second Chinese application, for glycemic control in adults with type 2 diabetes, was accepted in September 2026 (Hengrui diabetes filing).

Kailera announced the first KaiNETIC participants on January 12, 2026, and completed enrollment of about 4,900 participants at more than 200 sites in 11 countries on September 30, 2026. Its three studies evaluate weight change at 76 weeks, with topline results now expected in mid-2028 (enrollment completion):

KaiNETIC-3 is the interesting one. Kailera has said it wants to position ribupatide for people with high BMIs and greater disease burden, and this trial tests that claim against the most widely used injectable, semaglutide, rather than against placebo alone. The semaglutide arm is open-label, meaning participants know they are receiving it (January trial-design announcement).

Upcoming milestones

Sources: Kailera’s August 12 update, Kailera’s September 30 update, Hengrui’s August 4 update and Hengrui’s September 10 filing notice. These are developer forecasts for trials and results, not approval or release dates.

4. How Much Weight Loss Has Ribupatide Produced?

Injectable ribupatide: China Phase 2 and Phase 3

The number that put ribupatide on the map came from Hengrui’s Phase 2 trial: at the 8 mg dose, participants lost a mean of 23.6% of body weight at 36 weeks against 1.8% with placebo in the efficacy analysis, or 22.8% against 1.7% in the treatment-policy analysis, with no plateau in sight. Participants spent only the last 12 weeks at the full 8 mg dose (Kailera prospectus, Kailera program overview). That is the figure most often quoted for the drug.

The larger Phase 3 trial, HRS9531-301, enrolled 567 adults with obesity or overweight and a related complication, without diabetes. At 48 weeks, the sponsor reported up to 17.7% average weight loss, a 16.3 percentage-point difference from placebo, in the primary analysis, which counts everyone randomized regardless of whether they stayed on treatment. A supplementary analysis assuming continued treatment reported up to 19.2% (July 2025 Phase 3 report).

The drop from 23.6% to 17.7% between Phase 2 and Phase 3 is not unusual. Phase 3 trials are larger, less selected, and analyzed more conservatively, and the two figures use different durations and analysis methods. It does mean the 23.6% headline should be treated as a ceiling rather than an expectation.

Oral ribupatide: China Phase 2

The tablet study randomized 166 adults with obesity and no type 2 diabetes to three trial doses or placebo for 26 weeks (Oral Phase 2 report).

The often-quoted 12.1% result uses the supplementary efficacy analysis for the 25 mg and 50 mg groups, rather than the treatment-policy analysis shown above. Either way, two things stand out. Weight was still falling at week 26, so a longer trial could show more. And the 50 mg dose did no better than 25 mg on any measure: 59.1% of the 25 mg group and 52.5% of the 50 mg group lost at least 10%, and 38.6% and 37.5% lost at least 15%, against 4.8% at 10 mg, for the same 15% threshold. The 25 mg dose looks like the practical one (ADA 2026 presentation, ADA abstract).

5. What Did the Diabetes Trial Show?

Hengrui’s HRS9531-303 trial tested the injection in Chinese adults with type 2 diabetes not controlled on metformin, with or without an SGLT2 inhibitor, against semaglutide 1 mg rather than placebo. At week 36, the 4 mg dose lowered HbA1c by 2.78 percentage points versus 2.29 for semaglutide, a statistically significant advantage, and the 2 mg dose reached 2.34 points, non-inferior to semaglutide. The share of participants who both reached an HbA1c below 7% and lost at least 5% of body weight was 66.2% on 4 mg and 43.2% on 2 mg, against 42.8% on semaglutide (Hengrui August 2026 update).

Beating semaglutide on blood sugar in a head-to-head trial is a stronger result than beating placebo. Together with a placebo-controlled Phase 3 in 218 people managed on diet and exercise, where the 4 mg dose lowered HbA1c by 2.67 points, it underpins a Chinese diabetes application that the regulator accepted in September 2026 (Hengrui diabetes filing). The comparator dose matters, though: 1 mg is the standard diabetes dose of semaglutide, not the 2.4 mg used for weight management.

6. What Side Effects Have Been Reported?

In the oral Phase 2 trial, common reported events were nausea in 11.9%, 22.7% and 20.0% of the 10, 25 and 50 mg groups, diarrhea in 4.8%, 20.5% and 5%, and vomiting in 2.4%, 11.4% and 7.5%. The sponsor reported no permanent treatment discontinuations or dose reductions due to gastrointestinal events in the oral ribupatide groups (ADA safety report). Nausea rates in other oral GLP-1 programs vary widely with dose, titration and trial length, so cross-trial tolerability comparisons are unreliable.

The injection trials reported the pattern expected for the class: mostly mild to moderate gastrointestinal events during dose escalation, in both the Phase 3 obesity and diabetes studies. Detailed Phase 3 rates for the injection have not been published in a peer-reviewed paper, and the studies were too small and short to establish rare-event risks or long-term tolerability. Oral safety rates should not be applied to the injection or vice versa.

7. How Does It Compare With Tirzepatide?

Ribupatide and tirzepatide act on the same two receptors, and both are weekly injections, so the comparison is inevitable. No trial has made it, and cross-trial comparisons of weight-loss percentages are unreliable because populations, durations and analysis methods differ. On the numbers available, ribupatide’s Phase 3 result of 17.7% at 48 weeks lands in the same range as the approved GLP-1/GIP injection, not clearly above it.

What ribupatide can claim today is a head-to-head win over semaglutide 1 mg on HbA1c in diabetes, and a pending test against semaglutide 2.4 mg in high-BMI obesity. If it reaches the market in the United States, it will do so as a third weekly GLP-1/GIP injection after tirzepatide and possibly enicepatide, with the tablet as its distinguishing follow-on.

8. Ribupatide FAQ

• Are oral and injectable ribupatide the same product?

  They use the same molecule in different formulations, and they are at different stages. The injection is in global Phase 3; the tablet is in Phase 3 in China, and its global Phase 3 is planned for the first half of 2027. Evidence and any future prescribing instructions must be read separately.

• How much weight did people lose on ribupatide?

  The injection produced 23.6% mean weight loss at 36 weeks in a China Phase 2 trial at 8 mg, and up to 17.7% at 48 weeks in the larger China Phase 3, both against placebo. The tablet produced about 12% at 26 weeks. Different trials, populations and durations, so the numbers are not interchangeable.

• Is ribupatide approved in the United States?

  No. As of October 15, 2026, it remains investigational, with no confirmed U.S. launch date. The global Phase 3 injection trials finished enrollment in September 2026, results are expected in mid-2028, and a filing would follow those.

• Is ribupatide better than tirzepatide?

  Nobody knows. Both are weekly GLP-1/GIP injections, but no trial has compared them. The closest test is KaiNETIC-3, which runs ribupatide against open-label semaglutide 2.4 mg in people with a BMI of 35 or more; its results are due in mid-2028.

• Why develop both a pill and an injection?

  The injection delivers the larger weight loss and is the lead product. The tablet, which reached about 12% at 26 weeks with roughly one in five people reporting nausea, is aimed at people who will not inject or who want a lower-intensity option, and could serve as a maintenance step after injections.

9. Sources